Evolving Therapeutics develops phage-based solutions to combat bacterial infections and antimicrobial resistance. Their platform isolates, characterizes, and optimizes bacteriophages to specifically target and lyse bacteria, offering personalized and effective treatments that can also disrupt biofilms.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing prevalence of multidrug-resistant bacteria, coupled with the formation of recalcitrant biofilms, presents a significant challenge across human health, animal health, agriculture, and industrial sectors. Traditional antibiotic treatments are becoming less effective and can lead to toxic residues, necessitating the development of alternative therapeutic modalities.
Solution
Evolving Therapeutics develops phage-based solutions to combat bacterial infections and address antimicrobial resistance. Their platform isolates, characterizes, and optimizes bacteriophages, which are natural viruses that specifically target and lyse bacteria. This approach offers personalized, effective, and environmentally sustainable treatments that can also disrupt bacterial biofilms. By leveraging phage specificity, the company provides diagnostic, prophylactic, and therapeutic applications across various sectors, serving as a viable alternative to conventional antibiotics.
Target Audience
The company targets stakeholders in human healthcare, veterinary medicine, agriculture, and industrial bioprocessing that are seeking advanced solutions for bacterial infection control and antimicrobial resistance mitigation.
Features
- Phage isolation and characterization using advanced sequencing and electron microscopy techniques.
- Directed evolution methodologies for phage optimization to enhance efficacy and specificity.
- Scalable production of high-quality bacteriophages for therapeutic and diagnostic applications.
- Design of custom phage cocktails tailored to specific bacterial targets and biofilm structures.
- Development of rapid, real-time bacterial detection methods leveraging phage specificity.
- Prophylactic solutions to prevent bacterial infections and reduce antibiotic reliance.
- Targeted therapeutic applications that respect host microbiota and minimize environmental impact.
- "One Health" approach integrating solutions for human, animal, and environmental health.